Sort
10,766 grants matching “checkpoint inhibitor”
Targeting TERT in Melanoma
$470,176Jessie Villanueva · Wistar Institute · R01 · FY2020 · CA
Targeting epigenetic machinery to overcome myeloid cell-mediated resistance to anti-PD-1 therapy in GBM
$469,956Sangeeta Goswami · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA
Targeting epigenetic machinery to overcome myeloid cell-mediated resistance to anti-PD-1 therapy in GBM
$469,956Sangeeta Goswami · University Of Tx Md Anderson Can Ctr · R37 · FY2023 · CA
AHR-mediated immunosuppression in glioblastoma
$469,890Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2023 · ES
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion
$469,883Beth A Weaver · University Of Wisconsin-Madison · R01 · FY2022 · CA
Non-canonical roles of Mitotic Arrest Deficient 1 (Mad1) in tumor promotion
$469,883Beth A Weaver · University Of Wisconsin-Madison · R01 · FY2025 · CA
Health-associated oral bacteria as anti-cancer and immunomodulatory agents in oral cancer
$469,830Nezar Al-Hebshi · Temple Univ Of The Commonwealth · R21 · FY2024 · DE
LKB1/AMPK Signaling and Peutz-Jeghers Syndrome
$469,609Lewis C Cantley · Brigham And Women'S Hospital · P01 · FY2010 · CA
Unravel the novel role of S100A7 and its functional partners in Metastatic Triple Negative Breast Cancer Racial Disparity
$469,544Ramesh K Ganju · Ohio State University · R01 · FY2024 · CA
Unravel the novel role of S100A7 and its functional partners in Metastatic Triple Negative Breast Cancer Racial Disparity
$469,544Ramesh K Ganju · Ohio State University · R01 · FY2025 · CA
Project 3: Chemotherapy and Immunotherapy Biomarker Development for Triple Negative Breast Cancer
$469,334Charles M Perou · Univ Of North Carolina Chapel Hill · P50 · FY2022 · CA
Project 3: Chemotherapy and Immunotherapy Biomarker Development for Triple Negative Breast Cancer
$469,225Charles M Perou · Univ Of North Carolina Chapel Hill · P50 · FY2021 · CA
Genetic screens for IR resistance
$469,009Stephen J Elledge · Dana-Farber Cancer Inst · U19 · FY2006 · AI
Membrane-based immunotherapy for triple negative breast cancer- a partnered approach
$468,979Periasamy Selvaraj · Emory University · R01 · FY2019 · CA
ALDH Inhibition as Modulator of Tumor Immunobiology
$468,896Ronald J Buckanovich · Magee-Women'S Res Inst And Foundation · R01 · FY2020 · CA
Molecular Mechanisms of Bladder Cancer Immunometabolism
$468,881Liuqing Yang · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA
Binding of MMP13 to Immune Checkpoint Receptor PD-1H links Bone Disease with Immune Suppression in Multiple Myeloma
$468,878Suzanne Lentzsch · Columbia University Health Sciences · R01 · FY2023 · CA
Targeting the innate immune response in HNSCC
$468,514Judith A. Varner · University Of California, San Diego · R01 · FY2019 · DE
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
$468,386Wei Gu · Columbia University Health Sciences · R01 · FY2025 · CA
Co-regulation of p53 and PD-L1 by the VPRBP-USP2 axis in transcription and ubiquitylation
$468,386Wei Gu · Columbia University Health Sciences · R01 · FY2022 · CA
Targeting UHRF1 in combinational immunotherapy
$468,277Xiao-Fan Wang · Duke University · R01 · FY2021 · CA
Targeting the innate immune response in HNSCC
$468,267Judith A. Varner · University Of California, San Diego · R01 · FY2020 · DE
Targeting the innate immune response in HNSCC
$468,267Judith A. Varner · University Of California, San Diego · R01 · FY2018 · DE
Targeting the innate immune response in HNSCC
$468,267Judith A. Varner · University Of California, San Diego · R01 · FY2021 · DE
Mechanisms of cell death in cutaneous melanoma
$468,265Andrew E Aplin · Thomas Jefferson University · R01 · FY2023 · CA